--- title: "Scheduled Monitoring | Kisqali®" description: "Explore Kisqali monitoring in EBC: ends after cycle 6 unless clinically required; more frequent checks advised for grade ≥2 abnormalities." canonical_url: "https://www.kisqali.com/early-breast-cancer/monitoring-and-dosing/scheduled-monitoring" meta: "og:description": "Explore Kisqali monitoring in EBC: ends after cycle 6 unless clinically required; more frequent checks advised for grade ≥2 abnormalities." "og:title": "Scheduled Monitoring" --- ## **Scheduled monitoring** ### **KISQALI monitoring requirements. **⁽¹⁾ **KISQALI monitoring requirements** have been simplified and there is no scheduled monitoring beyond cycle 6, unless clinically indicated. ⁽¹⁾ ![Monitoring schedule diagram for KISQALI treatment showing timing of CBC, LFT, electrolytes, and ECG assessments from baseline through cycles 1 to 6. CBC and LFTs are assessed regularly at baseline, Day 14 of Cycle 1, Day 1 of Cycles 2–6. Electrolytes and ECGs are monitored at baseline, Day 1 of Cycle 1, and Day 1 of Cycle 2, with no routine checks after unless clinically indicated.](https://www.kisqali.com/img/early-breast-cancer/mobile/kisqali-monitoring-schedule-cycles-1-to-6.svg) \* If grade ≥2 abnormalities are observed, more frequent monitoring is recommended. ⁽¹⁾ ^† Correct electrolyte abnormalities prior to and during treatment. Monitoring of serum electrolytes should include potassium, calcium, phosphorus and magnesium. ⁽¹⁾ ^‡ Only initiate KISQALI in patients with QTcF <450 ms. In case of QTcF prolongation during therapy, more frequent assessments are recommended. Beyond cycle 1, ECG monitoring is only required as clinically indicated. ⁽¹⁾ ## Sitemap See the full [sitemap](/sitemap.md) for all pages.